Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Lutetium Lu 177 Dotatate Injection for SSTR+ GEP-NETs

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

The FDA has approved Lutetium Lu 177 Dotatate injection for treating adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs), providing a new targeted radiopharmaceutical therapy option.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You can now explore clinical applications and partnerships centred on Lutetium Lu 177 Dotatate for treating neuroendocrine tumours in the US. This approval opens a clear route for drug developers focusing on radiopharmaceutical cancer treatments.

◆ Coverage

1 source · 15 Sep 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfda-approvalradiopharmaceuticalgep-netsoncologydrug-therapy